201. Major depression, physical health and molecular senescence markers abnormalities.
- Author
-
Seitz-Holland J, Mulsant BH, Reynolds CF 3rd, Blumberger DM, Karp JF, Butters MA, Mendes-Silva AP, Vieira EL, Tseng G, Lenze EJ, and Diniz BS
- Abstract
Previous studies suggested the role of cellular senescence in late-life depression (LLD). However, it is unclear how this finding relates to common features of LLD, such as medical and cognitive problems. We applied factor analyses to an extensive battery of clinical variables in 426 individuals with LLD. Here we tested the relationship between these factors, age and sex, with an index of cellular senescence based on 22 senescence-associated secretory phenotype proteins. We found four factors: 'depression and anxiety severity', 'cognitive functioning', 'cardiovascular and cardiometabolic health' and 'blood pressure'. A higher senescence-associated secretory phenotype index was associated with poorer 'cognitive functioning' and 'cardiovascular and cardiometabolic health' but not with 'depression and anxiety severity'. These findings highlight the role of cellular senescence in poorer physical and cognitive health in LLD. They are consonant with the viewpoint that co-occurring medical burdens and their associated disabilities are part of a phenotype of accelerated ageing in LLD., Competing Interests: E.J.L. is a consultant for Prodeo, IngenioRx, Pritikin ICR and Boehringer-Ingelheim, has a patent application for sigma-1 agonists in COVID-19 treatment and receives research support from PCORI, COVID Early Treatment Fund, Emergent Venture FastGrants and MagStim. J.F.K. reports receiving an honorarium from Otsuka for the preparation and presentation of a webinar (disease-state, not product focused), from NightWare and Biogen for scientific advising and potential equity from Aifred Health for scientific advising. B.H.M. holds and receives support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He also receives compensation from the Centre for Addiction and Mental Health (CAMH) and the University of Toronto, Ontario. He currently receives research support from Brain Canada, the Canadian Institutes of Health Research, the CAMH Foundation, the US National Institute of Health (NIH), Capital Solution Design LLC (software used in a study funded by CAMH Foundation) and HAPPYneuron (software used in a study funded by Brain Canada). Within the past 3 years, he has received research support from the Patient-Centered Outcomes Research Institute (PCORI), and he has been an unpaid consultant to Myriad Neuroscience. D.M.B. receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. He has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. The other co-authors do not have a conflict of interest related to this study.
- Published
- 2023
- Full Text
- View/download PDF